IN2014MN02164A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02164A IN2014MN02164A IN2164MUN2014A IN2014MN02164A IN 2014MN02164 A IN2014MN02164 A IN 2014MN02164A IN 2164MUN2014 A IN2164MUN2014 A IN 2164MUN2014A IN 2014MN02164 A IN2014MN02164 A IN 2014MN02164A
- Authority
- IN
- India
- Prior art keywords
- activatable antibodies
- egfr
- moiety
- antibody
- variety
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 abstract 3
- 108060006698 EGF receptor Proteins 0.000 abstract 3
- 230000000873 masking effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639796P | 2012-04-27 | 2012-04-27 | |
US201261662204P | 2012-06-20 | 2012-06-20 | |
US201361749220P | 2013-01-04 | 2013-01-04 | |
US201361749529P | 2013-01-07 | 2013-01-07 | |
US201361763237P | 2013-02-11 | 2013-02-11 | |
PCT/US2013/038540 WO2013163631A2 (en) | 2012-04-27 | 2013-04-26 | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02164A true IN2014MN02164A (zh) | 2015-08-28 |
Family
ID=49484042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2164MUN2014 IN2014MN02164A (zh) | 2012-04-27 | 2013-04-26 |
Country Status (19)
Country | Link |
---|---|
US (5) | US9120853B2 (zh) |
EP (1) | EP2841093A4 (zh) |
JP (2) | JP2015516813A (zh) |
KR (1) | KR102138743B1 (zh) |
CN (2) | CN110078827A (zh) |
AU (2) | AU2013251310B2 (zh) |
BR (1) | BR112014026354A2 (zh) |
CA (1) | CA2871458C (zh) |
CO (1) | CO7160045A2 (zh) |
HK (1) | HK1204581A1 (zh) |
IL (2) | IL235331A0 (zh) |
IN (1) | IN2014MN02164A (zh) |
MX (1) | MX2014013041A (zh) |
PE (1) | PE20150605A1 (zh) |
PH (1) | PH12014502641B1 (zh) |
RU (1) | RU2713121C2 (zh) |
SG (1) | SG11201406943XA (zh) |
WO (1) | WO2013163631A2 (zh) |
ZA (2) | ZA201407715B (zh) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106995495A (zh) | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
EP2403964B1 (en) | 2009-03-02 | 2021-09-08 | Massachusetts Institute of Technology | Methods and products for in vivo enzyme profiling |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
US9120853B2 (en) | 2012-04-27 | 2015-09-01 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
CA2896282C (en) | 2013-01-04 | 2021-07-20 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
AU2014240012A1 (en) * | 2013-03-15 | 2015-09-24 | Abbvie Inc. | Antibody drug conjugate (ADC) purification |
JP6545666B2 (ja) | 2013-05-28 | 2019-07-17 | ディーシービー−ユーエスエー エルエルシーDcb−Usa Llc | タンパク質薬物の不活性化のための抗体ロッカー |
ES2828985T3 (es) | 2013-06-07 | 2021-05-28 | Massachusetts Inst Technology | Detección basada en la afinidad de biomarcadores sintéticos codificados por ligando |
EP3016980B1 (en) * | 2013-07-05 | 2020-05-06 | Formation Biologics Inc. | Egfr antibody conjugates |
CN105722859B (zh) | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
JP6915987B2 (ja) | 2013-09-25 | 2021-08-11 | シトムクス セラピューティクス,インコーポレイティド | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
IL302642A (en) * | 2014-01-31 | 2023-07-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and U-plasminogen and other cleavable groups, preparations containing them and their uses |
DK3536776T3 (da) * | 2014-04-29 | 2024-01-15 | Novartis Ag | Hidtil ukendte vertebratceller og fremgangsmåder til rekombinant ekspression af et polypeptid af interesse |
WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
CN104910275A (zh) * | 2014-12-04 | 2015-09-16 | 上海张江生物技术有限公司 | 一种新型抗表皮生长因子受体抗体、其制备方法及用途 |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
MX2017011644A (es) * | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
HUE057720T2 (hu) * | 2015-05-04 | 2022-06-28 | Cytomx Therapeutics Inc | Aktiválható anti-CD71 antitestek és ezek alkalmazási eljárásai |
WO2016179335A1 (en) * | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
RS60222B1 (sr) | 2015-05-04 | 2020-06-30 | Cytomx Therapeutics Inc | Anti-cd166 antitela koja mogu da se aktiviraju i postupci za njihovu upotrebu |
US20160362469A1 (en) * | 2015-06-12 | 2016-12-15 | Tianxin Wang | Methods for protein modification in pharmaceutical applications |
WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
EP3313874B1 (en) | 2015-06-26 | 2021-03-10 | University of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
WO2017019729A1 (en) | 2015-07-27 | 2017-02-02 | The General Hospital Corporation | Antibody derivatives with conditionally enabled effector function |
US11713358B2 (en) | 2015-08-28 | 2023-08-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
CN105399830B (zh) * | 2015-09-08 | 2019-11-19 | 北京天广实生物技术股份有限公司 | 抗egfr人源化单克隆抗体、其制备方法及用途 |
CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药(上海)有限公司 | 可活化的嵌合受体 |
EA039736B1 (ru) * | 2015-09-15 | 2022-03-04 | Сайтомкс Терапьютикс, Инк. | Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения |
MA43135A (fr) | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes pour le du traitement du cancer |
KR20180083868A (ko) | 2015-10-30 | 2018-07-23 | 알레타 바이오쎄라퓨틱스, 인크. | 종양 형질도입용 조성물 및 방법 |
ES2873846T3 (es) | 2015-11-19 | 2021-11-04 | Revitope Ltd | Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas |
US11225520B2 (en) | 2016-02-16 | 2022-01-18 | Dana-Farber Cancer Institute, Inc. | Immunotherapy compositions and methods |
EP3440013A4 (en) | 2016-04-08 | 2021-03-17 | Massachusetts Institute of Technology | METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES |
WO2017193070A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
AU2017355446A1 (en) * | 2016-11-03 | 2019-05-02 | Bristol-Myers Squibb Company | Activatable anti-CTLA-4 antibodies and uses thereof |
CA3042276A1 (en) | 2016-12-09 | 2018-06-14 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
KR20190134654A (ko) * | 2017-03-09 | 2019-12-04 | 싸이톰스 테라퓨틱스, 인크. | Cd147 항체, 활성화가능한 cd147 항체, 그리고 이를 만들고, 이용하는 방법 |
CA3059358A1 (en) | 2017-04-07 | 2018-10-11 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
WO2019014586A1 (en) | 2017-07-14 | 2019-01-17 | Cytomx Therapeutics, Inc. | ANTI-CD166 ANTIBODIES AND USES THEREOF |
CN110998329A (zh) * | 2017-07-20 | 2020-04-10 | 西托姆克斯治疗公司 | 定性和/或定量分析可活化抗体的特性的方法及其用途 |
WO2019036433A2 (en) | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION |
IL273119B2 (en) | 2017-09-08 | 2023-10-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
KR20200064096A (ko) | 2017-10-14 | 2020-06-05 | 싸이톰스 테라퓨틱스, 인크. | 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법 |
WO2019113386A1 (en) * | 2017-12-07 | 2019-06-13 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
US11891426B2 (en) | 2017-12-15 | 2024-02-06 | Aleta Biotherapeutics Inc. | CD19 variants |
CA3089287A1 (en) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
WO2019183218A1 (en) | 2018-03-20 | 2019-09-26 | Cytomx Therapeutics, Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
CN113840832A (zh) | 2018-05-14 | 2021-12-24 | 狼人治疗公司 | 可活化白介素-2多肽及其使用方法 |
JP2021523741A (ja) | 2018-05-14 | 2021-09-09 | ウェアウルフ セラピューティクス, インコーポレイテッド | 活性化可能なインターロイキン12ポリペプチド及びその使用方法 |
WO2019222282A1 (en) * | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
US11153281B2 (en) | 2018-12-06 | 2021-10-19 | Bank Of America Corporation | Deploying and utilizing a dynamic data stenciling system with a smart linking engine |
US11835522B2 (en) | 2019-01-17 | 2023-12-05 | Massachusetts Institute Of Technology | Sensors for detecting and imaging of cancer metastasis |
CN114390938A (zh) | 2019-03-05 | 2022-04-22 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
WO2020247867A2 (en) * | 2019-06-06 | 2020-12-10 | Janux Therapeutics, Inc. | Tumor activated t cell engagers and methods of use thereof |
US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
JP2022548310A (ja) * | 2019-09-23 | 2022-11-17 | シートムエックス セラピューティクス,インコーポレイテッド | 抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法 |
WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
CA3165414A1 (en) * | 2020-01-17 | 2021-07-22 | Aetio Biotherapy, Inc. | Pro-antibody that reduces off-target toxicity |
EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc | PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY |
CA3174665A1 (en) | 2020-04-09 | 2021-10-14 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
JP2023547978A (ja) * | 2020-08-11 | 2023-11-15 | ジャナックス セラピューティクス,インク. | 切断可能リンカー組成物および方法 |
JP2023552812A (ja) | 2020-12-09 | 2023-12-19 | ジャナックス セラピューティクス,インク. | Psmaおよびエフェクタ細胞抗原を標的とする腫瘍活性化抗体に関連する組成物ならびに方法 |
WO2022240637A2 (en) * | 2021-05-12 | 2022-11-17 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens |
US20230183382A1 (en) | 2021-10-15 | 2023-06-15 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
WO2023064929A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
WO2023148388A1 (en) * | 2022-02-04 | 2023-08-10 | Zytox Therapeutics Ab | Fusion protein comprising an egfr-binding domain and a masking domain |
WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
WO2024046396A1 (zh) * | 2022-08-31 | 2024-03-07 | 洪明奇 | 抗meEGFR抗体、其抗原结合片段及其用途 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
PL174721B1 (pl) | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
US6455247B1 (en) | 1996-01-23 | 2002-09-24 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
TW505653B (en) | 1996-02-26 | 2002-10-11 | Meiji Seika Co | Triterpene derivatives possessing an effect of treating liver diseases and pharmacentical compositions containing the same |
JP2001505872A (ja) | 1996-09-09 | 2001-05-08 | ジーランド ファーマシューティカルズ アクティーゼルスカブ | α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ |
US20040010134A1 (en) * | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
ATE513563T1 (de) | 2000-10-09 | 2011-07-15 | Isis Innovation | Therapeutische und toleranz-induzierende antikörper |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
EP1434778A4 (en) * | 2001-05-31 | 2005-07-13 | Medarex Inc | CYTOTOXINS, PROMEDICAMENTS, BINDERS AND STABILIZERS USEFUL THEREFOR |
US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
US20040111757A1 (en) * | 2002-12-05 | 2004-06-10 | Dongxiao Zhang | Multiplex system for production and screening of monoclonal antibodies |
US8088387B2 (en) * | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
TW200539855A (en) * | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
WO2007105027A1 (en) * | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
EP2446904B1 (en) | 2006-05-30 | 2015-04-29 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
SG175615A1 (en) | 2006-06-06 | 2011-11-28 | Genentech Inc | Anti-dll4 antibodies and methods using same |
US8450068B2 (en) * | 2007-02-16 | 2013-05-28 | University Of Virginia Patent Foundation | IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis |
US9040666B2 (en) | 2007-07-13 | 2015-05-26 | Bac Ip B.V. | Single-domain antigen-binding proteins that bind mammalian IgG |
WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
WO2009025846A2 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
EP2615115A3 (en) * | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
US8541178B2 (en) | 2008-05-13 | 2013-09-24 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
WO2010077643A1 (en) | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Masking ligands for reversible inhibition of multivalent compounds |
US8895702B2 (en) * | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
CN106995495A (zh) | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | 修饰抗体组合物及其制备和使用方法 |
WO2010129609A2 (en) | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | Antibodies and methods of use thereof |
US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
WO2013043071A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
US9120853B2 (en) | 2012-04-27 | 2015-09-01 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
CA2913732A1 (en) | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
CN105722859B (zh) | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
-
2013
- 2013-04-26 US US13/872,052 patent/US9120853B2/en active Active
- 2013-04-26 CA CA2871458A patent/CA2871458C/en not_active Expired - Fee Related
- 2013-04-26 AU AU2013251310A patent/AU2013251310B2/en not_active Ceased
- 2013-04-26 PE PE2014001901A patent/PE20150605A1/es active IP Right Grant
- 2013-04-26 WO PCT/US2013/038540 patent/WO2013163631A2/en active Application Filing
- 2013-04-26 CN CN201910284451.5A patent/CN110078827A/zh active Pending
- 2013-04-26 IN IN2164MUN2014 patent/IN2014MN02164A/en unknown
- 2013-04-26 SG SG11201406943XA patent/SG11201406943XA/en unknown
- 2013-04-26 KR KR1020147032521A patent/KR102138743B1/ko active IP Right Grant
- 2013-04-26 EP EP13780884.6A patent/EP2841093A4/en not_active Withdrawn
- 2013-04-26 RU RU2014147684A patent/RU2713121C2/ru active
- 2013-04-26 MX MX2014013041A patent/MX2014013041A/es active IP Right Grant
- 2013-04-26 JP JP2015509207A patent/JP2015516813A/ja active Pending
- 2013-04-26 CN CN201380033414.8A patent/CN104540518A/zh active Pending
- 2013-04-26 BR BR112014026354A patent/BR112014026354A2/pt not_active IP Right Cessation
-
2014
- 2014-10-23 ZA ZA2014/07715A patent/ZA201407715B/en unknown
- 2014-10-26 IL IL235331A patent/IL235331A0/en active IP Right Grant
- 2014-10-27 CO CO14237235A patent/CO7160045A2/es unknown
- 2014-11-26 PH PH12014502641A patent/PH12014502641B1/en unknown
-
2015
- 2015-06-03 HK HK15105286.5A patent/HK1204581A1/zh unknown
- 2015-07-31 US US14/815,111 patent/US9545442B2/en active Active
- 2015-10-21 ZA ZA2015/07859A patent/ZA201507859B/en unknown
-
2016
- 2016-12-16 US US15/381,972 patent/US9889211B2/en active Active
-
2018
- 2018-01-19 US US15/875,947 patent/US10709799B2/en active Active
- 2018-05-10 AU AU2018203262A patent/AU2018203262A1/en not_active Abandoned
-
2019
- 2019-02-01 JP JP2019017216A patent/JP2019108331A/ja active Pending
- 2019-04-02 IL IL265788A patent/IL265788A/en unknown
-
2020
- 2020-06-04 US US16/892,973 patent/US11890354B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02164A (zh) | ||
WO2015066279A3 (en) | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof | |
WO2014052462A3 (en) | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof | |
PH12015500125A1 (en) | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof | |
EP2566890A4 (en) | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE | |
TN2015000396A1 (en) | Antibody drug conjugates | |
CL2015000582A1 (es) | Anticuerpos anti-mcam y métodos asociados de uso | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
NZ604003A (en) | Monoclonal antibodies against her2 | |
AU2012335543A8 (en) | HER3 antibodies and uses thereof | |
PH12014501427A1 (en) | Anti-php-tau antibodies and their uses | |
EP4249065A3 (en) | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors | |
NZ608033A (en) | Anti-ox40 antibodies and methods of using the same | |
IN2014KN00848A (zh) | ||
AU2011338480A8 (en) | Humanized antibodies to LIV-1 and use of same to treat cancer | |
PE20151926A1 (es) | Anticuerpos de receptores de antitransferrina y metodos de uso | |
MX2012007676A (es) | Nueva formulacion de anticuerpo. | |
MX2013011353A (es) | Conjugados de anticuerpos-farmaco. | |
NZ601588A (en) | Methods for treating breast cancer | |
MY201478A (en) | Antibodies and assays for detection of folate receptor 1 | |
MX2013011706A (es) | Proteinas novedosas de enlace a antigeno. | |
BRPI1014544B8 (pt) | anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
NZ611785A (en) | Anti-notch1 antibodies | |
TR201903312T4 (tr) | Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri. |